Our patients need help. This year, diagnoses and treatments for every kind of condition have been delayed, patients have found it harder than ever to access and pay for care, and they’re facing undreamed-of challe

CHALLENGE – A “DUMPSTER DIVE“ We were approached by a client with a challenge we’d seen before: a robust and active SFMC instance with thousands of data points but no documentation history. The client

COVID-19 has placed a spotlight on healthcare disparities, and is hitting historically under-resourced communities disproportionately hard — in particular, people who identify as BIPOC (Black, indigenous, and peop

When the results of the COVID-19 pandemic hit businesses, it did not spare healthcare providers’ practices. The effects on those offices, on the roles of the healthcare sales reps that call on them, and on public

Guest post by Paul Pierce – SVP, Professional Services Since the implementation of the General Data Protection Regulation (GDPR) for the EU in 2018 and the plethora of companion regulations such as Canada’s Anti-S

Recently, the publishers of Fierce Pharma and Fierce Biotech, Fierce Life Sciences, (also producers of Digital Pharma East and dozens of other events) put on their first all-virtual conference, Digital Pharma Week

Guest post by Carolyn Hathaway, Campaign Management Senior Specialist Good email marketing takes investment. Developing strategy, setting up a platform, acquiring leads, crafting content – it all requires time, ef

The COVID-19 pandemic has completely upended the ways in which healthcare professionals (HCPs) interact with patients. The concept of point of care – the moments when healthcare professionals (HCPs) – has transfor

All marketers love data. But more accurately, what all marketers love are insights – new points of understanding that have been gleaned from accurate, timely, tidy, well-organized, well-analyzed, well-understood d

Intouch Group and DHC Group set out to create to create the most comprehensive, data-driven, forward-looking paper on the longer-term implications of the COVID-19 pandemic on U.S. pharmaceutical commercial organiz